JASPER THERAPEUTICS, INC
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 45
- Market Cap
- $305.8M
Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06736262
- Locations
- 🇺🇸
Investigative Site 105, San Diego, California, United States
🇺🇸Investigative Site 123, Lafayette, Louisiana, United States
🇩🇪Investigative Site 210, München, Bavaria, Germany
A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants with Allergic Asthma
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06592768
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦University of Alberta, Edmonton, Alberta, Canada
🇨🇦University of British Columbia, Vancouver, British Columbia, Canada
A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT06353971
- Locations
- 🇩🇪
Charité - University Clinic Berlin, Berlin, Germany
🇩🇪University Hospital Dresden, Dresden, Germany
🇩🇪Medical University Hannover, Hannover, Germany
Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU)
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Other: Placebo
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06162728
- Locations
- 🇺🇸
Site 118, Birmingham, Alabama, United States
🇺🇸Little Rock Allergy & Asthma Clinical Research Center, Little Rock, Arkansas, United States
🇺🇸Site 117, Fremont, California, United States
JSP191 (briquilimab) in Subjects with LR-MDS
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Jasper Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05903274
- Locations
- 🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
- Prev
- 1
- 2
- Next